Cibc World Market Inc. Acquires 60,635 Shares of AbbVie Inc. $ABBV

Cibc World Market Inc. boosted its holdings in AbbVie Inc. (NYSE:ABBV) by 10.2% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 657,272 shares of the company’s stock after purchasing an additional 60,635 shares during the quarter. Cibc World Market Inc.’s holdings in AbbVie were worth $152,185,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in shares of AbbVie by 1.9% in the 2nd quarter. Vanguard Group Inc. now owns 177,298,707 shares of the company’s stock valued at $32,910,186,000 after acquiring an additional 3,380,842 shares in the last quarter. Geode Capital Management LLC grew its holdings in AbbVie by 2.4% in the second quarter. Geode Capital Management LLC now owns 39,178,351 shares of the company’s stock worth $7,240,169,000 after purchasing an additional 924,761 shares during the period. Charles Schwab Investment Management Inc. increased its stake in AbbVie by 6.0% in the second quarter. Charles Schwab Investment Management Inc. now owns 26,783,329 shares of the company’s stock valued at $4,970,848,000 after purchasing an additional 1,517,222 shares in the last quarter. Norges Bank bought a new stake in AbbVie in the second quarter valued at $4,288,200,000. Finally, Raymond James Financial Inc. raised its holdings in shares of AbbVie by 41.8% during the second quarter. Raymond James Financial Inc. now owns 9,337,480 shares of the company’s stock valued at $1,733,222,000 after purchasing an additional 2,753,312 shares during the period. 70.23% of the stock is owned by institutional investors and hedge funds.

AbbVie Trading Down 0.4%

Shares of AbbVie stock opened at $222.32 on Wednesday. The company has a market capitalization of $392.93 billion, a P/E ratio of 94.20, a price-to-earnings-growth ratio of 0.78 and a beta of 0.35. The stock has a fifty day simple moving average of $223.67 and a 200 day simple moving average of $220.29. AbbVie Inc. has a 12-month low of $164.39 and a 12-month high of $244.81.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 4,184.47%. The firm had revenue of $16.62 billion for the quarter, compared to the consensus estimate of $16.39 billion. During the same period in the previous year, the firm earned $2.16 EPS. The business’s revenue for the quarter was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, analysts predict that AbbVie Inc. will post 12.31 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have recently commented on ABBV. Piper Sandler restated an “overweight” rating and issued a $289.00 target price (up from $284.00) on shares of AbbVie in a research note on Wednesday, November 5th. Citigroup reduced their price objective on AbbVie from $235.00 to $230.00 and set a “neutral” rating for the company in a research note on Tuesday, January 27th. BMO Capital Markets restated an “outperform” rating and set a $258.00 price objective on shares of AbbVie in a report on Thursday, January 15th. UBS Group cut their target price on AbbVie from $240.00 to $230.00 and set a “neutral” rating on the stock in a report on Thursday, February 5th. Finally, HSBC raised shares of AbbVie from a “hold” rating to a “buy” rating and lifted their price target for the company from $225.00 to $265.00 in a research report on Wednesday, December 10th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat, AbbVie has a consensus rating of “Moderate Buy” and an average target price of $251.00.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.